To test whether DDX41 also opposes DSBs and genomic instability in hematopoietic stem and progenitor cells (HSPCs) in which loss-of-function mutations of DDX41 result in AML, we depleted DDX41 in human CD34+ HSPCs, and monitored DSBs using 53BP1 foci. This evidence concerns the gene CD34 and acute myeloid leukemia.